Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.99 USD
-0.14 (-12.48%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.01 +0.02 (2.12%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Aptevo Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 17 | 23 | 46 | 43 | 12 |
Receivables | 0 | 3 | 4 | 2 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 6 |
Other Current Assets | 2 | 2 | 3 | 2 | 4 |
Total Current Assets | 19 | 27 | 53 | 47 | 30 |
Net Property & Equipment | 1 | 1 | 2 | 3 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 4 |
Deposits & Other Assets | 0 | 0 | 0 | 1 | 11 |
Total Assets | 25 | 34 | 57 | 54 | 53 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 3 | 6 | 13 |
Current Portion Long-Term Debt | 0 | 2 | 12 | 5 | 20 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 3 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 18 | 1 | 2 |
Total Current Liabilities | 7 | 9 | 35 | 15 | 38 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 4 | 20 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 16 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 16 | 55 | 37 | 42 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 236 | 224 | 215 | 202 | 180 |
Retained Earnings | -223 | -206 | -214 | -186 | -168 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 18 | 1 | 17 | 12 |
Total Liabilities & Shareholder's Equity | 25 | 34 | 57 | 54 | 53 |
Total Common Equity | 12 | 18 | 1 | 17 | 12 |
Shares Outstanding | 0.40 | 0.10 | 0.10 | 0.10 | 0.00 |
Book Value Per Share | 30.55 | 179.70 | 12.20 | 165.90 | 11.84 |
Fiscal Year End for Aptevo Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 17 | 19 | 21 | 25 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 2 | 2 | 3 |
Total Current Assets | NA | 19 | 21 | 23 | 28 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 25 | 27 | 29 | 35 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 4 | 5 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 1 |
Total Current Liabilities | NA | 7 | 7 | 7 | 6 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 13 | 12 | 13 | 12 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 236 | 232 | 227 | 226 |
Retained Earnings | NA | -223 | -218 | -211 | -203 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 12 | 15 | 16 | 23 |
Total Liabilities & Shareholder's Equity | NA | 25 | 27 | 29 | 35 |
Total Common Equity | 0 | 12 | 15 | 16 | 23 |
Shares Outstanding | 0.40 | 0.40 | 0.30 | 0.10 | 0.10 |
Book Value Per Share | 0.00 | 30.55 | 49.07 | 162.50 | 232.60 |